Global strategy for asthma management and prevention.

GUIDELINE TITLE
Global strategy for asthma management and prevention.

BIBLIOGRAPHIC SOURCE(S)
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Bethesda (MD): Global Initiative for Asthma (GINA); 2009. 112 p. [820 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Bethesda (MD): Global Initiative for Asthma (GINA); 2008. 92 p. [383 references]
This guideline updates a previous version: Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI). Global strategy for asthma management and prevention. Bethesda (MD): Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI); 2007. 92 p. [372 references]
In an effort to keep the GINA Workshop report as up to date as possible, a GINA Science Committee has been established to review published research on asthma management and prevention, and to post yearly updates on the GINA Web site. See the GINA Web site for archived versions of the GINA guidelines.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

February 18, 2010 - Long-Acting Beta-Agonists (LABAs): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and consumers that, due to safety concerns, FDA is requiring a risk management strategy (REMS) and class-labeling changes for all LABAs. The REMS will require a revised Medication Guide written specifically for patients, and a plan to educate healthcare professionals about the appropriate use of LABAs.

July 1, 2009 – Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.

open here please to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15556&nbr=&string=


http://www.guideline.gov/summary/summary.aspx?view_id=1&doc_id=15556